Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

November 15, 2014 (Vol. 34, No. 20)

Ready, Aim, CRISPR (or RNAi)

When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.

  • Recent progress in probing gene function via the RNAi and CRISPR methods were a strong theme of the Discovery On Target conference, which took place last month in Boston. Both methods enable researchers to impair the function of a targeted gene. With RNAi (short for RNA interference), molecules ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.